Device Trial Radar · NCT03506308
Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae
Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
213
Planned (sponsor's estimate)
Start
Aug 7, 2018
Primary completion
Apr 2027
Study completion Apr 2030
Sponsor
- Lead sponsor
- C. R. BardPublic (BDX)
- Sponsor type
- Industry
- First posted
- Apr 24, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
Conditions
- Arteriovenous Fistula
Interventions
LUTONIX 035 Drug Coated Balloon PTA CatheterDevice
All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Target Lesion Primary Patency (TLPP)Time frame: 6 Months
- Percentage of Participants With No Primary Safety EventsTime frame: 30 days
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Flowers Hospital
Dothan, Alabama
St. Joseph Hospital of Orange
Orange, California
23 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.